Arterial Hypertension (AH) is the major cardiovascular risk factor in industrialized countries, showing very high prevalence, between 25%-38% of adult subjects in Italy and Europe. Through its complications (myocardial infarction, stroke, heart failure and kidney failure), AH is the leading cause of cardiovascular morbidity and premature mortality and disability. Nevertheless, worldwide the effective management of AH is very disappointing mainly because of the inadequate knowledge of AH as specific illness in the population and the still limited knowledge of the pathogenetic mechanisms. In addition, of course the lack of professionals with specific expertise in the field of AH and Vascular Biology, deriving from the absence, especially in Europe, of post-graduate specialized training programs in this area. This results in a severe shortage of doctors and researchers with specific skills that may find use in both clinical and industry in this area. International PhD Course in Arterial Hypertension and Vascular Biology (ARHYVAB) will merge in a large and well-established international research network, the existence of which is evidenced by the publications of the School faculty within several leading research groups in Europe and in the world in the field of Hypertension and Vascular Biology. L 'ARHYVAB aims to train highly qualified professionals with a degree awarded jointly by the Chancellors of several Universities-Partners. In particular, ARHYVAB aims at training two professional types: Researchers with skills to allow its use, in Italy and abroad, in academic and pharmaceutical industry background, in the planning, organizing, conducting clinical trials on hypertension blood and dissemination to the public of their results through conferences and publications. Objectives: 1. Skills that allow to plan, conduct and analyze researches in clinical and experimental level in the field of 'Hypertension and Vascular Biology. 2. Skills in the field of Molecular Genetics and pharmacogenomics of AH, a field of research that, by its nature, implies the need for integration of efforts and resources at European level. 3. Knowledge suitable for the insertion in research groups in the field of Cardiovascular Pharmacology, both academic and pharmaceutical industry, particularly as regards the preclinical and clinical development of new drug entities. 4. Ability to plan and conduct clinical trials in the field of hypertension. The PhD program will provide over the 3 years, a multidisciplinary training with skills which will allow the immediate integration of PhD students in highly specialized research groups.